Skip to content

Northeastern researchers find inhaling supplemental oxygen can awaken anti-tumor cells

Northeastern University researchers have found that inhaling supplemental oxygen—40 to 60 percent oxygen as opposed to the 21 percent oxygen in air—can weaken immunosuppression and awaken anti-tumor cells. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year. The breakthrough findings were published Wednesday in Science Translational Medicine.

Michail Sitkovsky, an immuno­phys­i­ology researcher at North­eastern Uni­ver­sity, and his team found that sup­ple­mental oxy­gena­tion inhibits the hypoxia-​​driven accu­mu­la­tion of adeno­sine in the tumor microen­vi­ron­ment and weakens immuno­sup­pres­sion. This, in turn, could improve cancer immunotherapy and shrink tumors by unleashing anti-​​tumor T lym­pho­cytes and nat­ural killer cells.

“Breathing sup­ple­mental oxygen opens up the gates of the tumor fortress and wakes up ‘sleepy’ anti-​​tumor cells, enabling these sol­diers to enter the fortress and destroy it,” explained Sitkovsky, the Eleanor W. Black Chair and Pro­fessor of Immuno­phys­i­ology and Phar­ma­ceu­tical Biotech­nology in the Bouvé College of Health Sciences’ Department of Pharmaceutical Sciences and the founding director of the university’s New Eng­land Inflam­ma­tion and Tissue Pro­tec­tion Insti­tute. “How­ever, if anti-​​tumor immune cells are not present, oxygen will have no impact.”

The find­ings build upon Sitkovsky’s pre­vious research and rep­re­sent the cul­mi­na­tion of his life’s work, which has been sup­ported by North­eastern and the National Insti­tutes of Health. In the early 2000s, Sitkovsky made an impor­tant dis­covery in immunology, which has come to inform his research in cancer biology. He found that a receptor on the sur­face of immune cells—the A2A adeno­sine receptor—is respon­sible for pre­venting T cells from invading tumors and for “putting to sleep” those killer cells that do manage to enter into the tumors.

His latest work shows that supplemental oxygen weakened tumor-​​protecting sig­naling through the A2A adeno­sine receptor and wakes up the T cells that were able to invade lung tumors.“This dis­covery shifts the par­a­digm of decades-​​long drug devel­op­ment, a process with a low suc­cess rate,” Sitkovsy said. “Indeed, it is promising that our method could be imple­mented rel­a­tively quickly by testing in clin­ical trials the effects of oxy­gena­tion in com­bi­na­tion with dif­ferent types of already existing immunother­a­pies of cancer.”

Sitkovsky noted that the effects of sup­ple­mental oxy­gena­tion might be even stronger in com­bi­na­tion with a syn­thetic agent that he calls “super-​​caffeine,” which is known to block the tumor-​​protecting effects of the adeno­sine receptor. He and Graham Jones, pro­fessor and chair of Northeastern’s Depart­ment of Chem­istry and Chem­ical Biology, are cur­rently col­lab­o­rating to design the next gen­er­a­tion of this drug, which was orig­i­nally devel­oped for patients with Parkinson’s disease.

“The anti-​​tumor effects of sup­ple­mental oxygen can be fur­ther improved by the nat­ural antag­o­nist of the A2A adeno­sine receptor, which hap­pens to be the caf­feine in your coffee,” Sitkovsky said. “People drink coffee because caf­feine pre­vents the A2A adeno­sine receptor in the brain from putting us to sleep.”

The paper—titled “Immuno­log­ical mech­a­nisms of the anti­tumor effects of sup­ple­mental oxygenation”—was the result of a robust inter­dis­ci­pli­nary col­lab­o­ra­tion between doc­tors and researchers at some of the country’s most pres­ti­gious uni­ver­si­ties, hos­pi­tals, and med­ical schools. Co-​​authors com­prised 12 researchers from NEITPI, the Northeastern-​​based con­sor­tium aimed at under­standing the under­lying causes and mol­e­c­ular mech­a­nisms of inflam­ma­tion; Barry Karger, the director of Northeastern’s Bar­nett Insti­tute of Chem­ical and Bio­log­ical Analysis; and doc­tors from the Uni­ver­sity of Pitts­burgh School of Med­i­cine, the Uni­ver­sity of Miami Miller School of Med­i­cine, Brigham and Women’s Hos­pital, and the Dana-​​Farber Cancer Insti­tute, where Sitkovsy holds an appoint­ment as a pres­i­den­tial scholar.

Cookies on Northeastern sites

This website uses cookies and similar technologies to understand your use of our website and give you a better experience. By continuing to use the site or closing this banner without changing your cookie settings, you agree to our use of cookies and other technologies. To find out more about our use of cookies and how to change your settings, please go to our Privacy Statement.